Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483854 | 0.87 | AGTR1 (0.47) | ACHEAGTR1LTB4R2 | |
| SCHEMBL3484286 | 0.86 | ACHE (0.45) | ACHEAGTR1LTB4R2 | |
| SCHEMBL3484638 | 0.86 | AGTR1 (0.44) | AGTR1LTB4R2 | |
| SCHEMBL13539734 | 0.85 | ACHE (0.61) | ACHEAGTR1LTB4R2 | |
| SCHEMBL3483930 | 0.85 | ACHE (0.42) | ACHEAGTR1LTB4R2 | |
| SCHEMBL3485301 | 0.84 | ACHE (0.43) | ACHEAGTR1LTB4R2 | |
| SCHEMBL13539757 | 0.76 | ACHE (0.63) | ACHEAGTR1LTB4R2 | |
| SCHEMBL3484198 | 0.76 | ACHE (0.70) | ACHEAGTR1LTB4R2 | |
| SCHEMBL13539749 | 0.75 | ACHE (0.62) | ACHEAGTR1LTB4R2 | |
| SCHEMBL13539541 | 0.74 | AGTR1 (0.62) | ACHEAGTR1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2049107-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | Genfit (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | ACHE 2077/4885AGTR1 1691/4885LTB4R2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.